Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ryan Woodhouse
Institution:
Foundation Medicine (United States)
Observed institution:
Foundation Medicine (United States)
ORCID:
0000-0002-0316-3759
Observed ORCID:
0000-0002-0316-3759
OpenAlex ID:
A5070120529
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
2020
·
Ryan Woodhouse
, Meijuan Li
, et al.
·
PLoS ONE
·
562
PDF
Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
2022
·
Rafal Dziadziuszko
, Tiffany Hung
, et al.
·
Molecular Oncology
·
21
PDF
Driver Mutation Variant Allele Frequency in Circulating Tumor DNA and Association with Clinical Outcome in Patients with Non–Small Cell Lung Cancer and EGFR- and KRAS-Mutated Tumors
2022
·
Meijuan Li
, Lei Yang
, et al.
·
Journal of Molecular Diagnostics
·
15
PDF
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
2022
·
Johannes Noé
, Walter Bordogna
, et al.
·
JTO Clinical and Research Reports
·
8
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene blood-based comprehensive genomic profiling assay.
2020
·
Ryan Woodhouse
, Lucas Dennis
, et al.
·
Journal of Clinical Oncology
·
8
Analytical validation and sequencing coverage studies suggest that performance of a liquid biopsy assay is tumor agnostic (DNA-is-DNA)
2025
·
Wei Meng
, Russell Petry
, et al.
·
PLoS ONE
·
1
PDF
Show more works
View as search
Works count:
6
Citation count:
615
H-index:
5
I10-index:
3
Year
Topic
Type